Sopharma AD-SofiaWAR:SPH 68 Altman Z-Score is 3.19 as of Jun. 29, 2026, which is 2% above its 10-year median of 3.12. GuruFocus rates WAR:SPH with a GF Score™ of 68/100 and a GF Value™ of zł12.97 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, Sopharma AD-Sofia ranks better than 67.52% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.17 is strong.
Sopharma AD-Sofia has a Altman Z-Score of 3.19, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Sopharma AD-Sofia's Altman Z-Score or its related term are showing as below:
WAR:SPH'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.23 Med: 3.12 Max: 3.91
Current: 3.17
During the past 13 years, Sopharma AD-Sofia's highest Altman Z-Score was 3.91. The lowest was 2.23. And the median was 3.12.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Sopharma AD-Sofia Altman Z-Score Related Terms
Sopharma AD-Sofia Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Altman Z-Score Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Sopharma AD-Sofia's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.1444
+
1.4
*
0.1945
+
3.3
*
0.0949
+
0.6
*
1.9324
+
1.0
*
1.2719
=
3.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sopharma AD-Sofia (WAR:SPH) has a Altman Z-Score of 3.19 as of Jun. 29, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sopharma AD-Sofia and its competitors. This is near median its historical median of 3.12. Over the past decade, Sopharma AD-Sofia's Altman Z-Score has ranged from 2.23 to 3.91. According to the industry distribution chart, Sopharma AD-Sofia ranks #38 out of 117 companies in the Medical Distribution industry, placing it in the top 32.5%.
Is Sopharma AD-Sofia's Altman Z-Score too high?
Sopharma AD-Sofia's current Altman Z-Score of 3.19 is near median its 10-year median of 3.12. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 3.91. The Medical Distribution industry median Altman Z-Score is 2.49. Sopharma AD-Sofia's value of 3.19 is 28.1% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #38 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Altman Z-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #38 out of 117 companies for Altman Z-Score. This puts Sopharma AD-Sofia in the upper half of its industry. The industry median Altman Z-Score is 2.49. Sopharma AD-Sofia's value of 3.19 is 28.1% above this benchmark. Historically, Sopharma AD-Sofia's own Altman Z-Score has ranged from 2.23 to 3.91 over the past decade. While the company's 10-year median is 3.12 vs. the industry median of 2.49, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.49, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Altman Z-Score of 3.19 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Altman Z-Score is 3.19, which is near median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł12.97, compared to a current price of zł7.92 — trading 38.9% below its estimated fair value. The current Altman Z-Score is 3.19, which is near median its 10-year median of 3.12 and 28.1% above the Medical Distribution industry median of 2.49. Sopharma AD-Sofia's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Altman Z-Score is 3.19 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.92 is trading 38.9% below its estimated GF Value™ of zł12.97.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Altman Z-Score: 3.19 (near median its 10-year median of 3.12)
GF Value™: zł12.97 vs. price of zł7.92 (38.9% below fair value)
Industry Position: 28.1% above the Medical Distribution median (#38 of 117)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
68GF Score
Get the complete analysis for WAR:SPH
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
